SSY Group Limited Stock

Equities

2005

KYG8406X1034

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:12 2024-06-14 am EDT 5-day change 1st Jan Change
4.88 HKD +5.63% Intraday chart for SSY Group Limited +1.88% -1.21%
Sales 2024 * 7.58B 971M Sales 2025 * 8.83B 1.13B Capitalization 14.49B 1.86B
Net income 2024 * 1.57B 201M Net income 2025 * 1.84B 236M EV / Sales 2024 * 1.91 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 1.64 x
P/E ratio 2024 *
9.25 x
P/E ratio 2025 *
7.83 x
Employees 5,640
Yield 2024 *
3.48%
Yield 2025 *
3.69%
Free-Float 41.1%
More Fundamentals * Assessed data
Dynamic Chart
SSY Group Gets Bulk Drug Registration Go-Ahead for Ischemic Stroke Drug in China MT
SSY Group Limited Announces Update on Product Development CI
SSY Group Limited Announces that the Group Has Obtained the Approval for Drug Production and Registration for Entacapone Tablets (0.2G) CI
SSY Group Gets Chinese Regulator’s Approval for Drug Production, Registration MT
Ssy Group Limited Announces that the Group has Obtained the Approval for Drug Production and Registration for Bisoprolol Fumarate and Amlodipine Besilate Tablets CI
SSY Group's Trelagliptin Succinate Gets Bulk Drug Approval in China MT
SSY Group Limited Obtains Trelagliptin Succinate Approval for Registration from the National Medical Products Administration of China CI
SSY Group’s Dialysis Solution Passes Generic Drug Evaluation in China MT
SSY Group Limited Provides Update on Product Development CI
SSY Obtains China Approval for Additional Specification, Generic Status of Metabolic Acidosis Drug MT
SSY Group Limited Announces Update on Product Development CI
SSY Group Gets China Approval for Chemotherapy-Induced Nausea Treatment MT
Ssy Group Limited Obtains Approvals for Drug Production and Registration for Ondansetron Hydrochloride Injection (4Ml:8Mg and 2Ml:4Mg) from National Medical Products Administration of China CI
SSY Group’s Bronchitis Drug Gets Registration Approval in China MT
Ssy Group Limited Announces That the Group's Formoterol Fumarate Has Obtained the Approval for Registration from the National Medical Products Administration CI
More news
1 day+5.63%
1 week+1.88%
Current month+3.61%
1 month-0.81%
3 months+2.31%
6 months+0.41%
Current year-1.21%
More quotes
1 week
4.59
Extreme 4.59
4.88
1 month
4.56
Extreme 4.56
4.97
Current year
3.88
Extreme 3.88
5.20
1 year
3.88
Extreme 3.88
5.22
3 years
2.50
Extreme 2.5
8.29
5 years
2.50
Extreme 2.5
9.00
10 years
1.69
Extreme 1.69
9.46
More quotes
Managers TitleAgeSince
Chief Executive Officer 67 -
Director of Finance/CFO 43 15-03-31
Director/Board Member 48 -
Members of the board TitleAgeSince
Chief Executive Officer 67 -
Director/Board Member 59 07-07-25
Director/Board Member 55 05-10-15
More insiders
Date Price Change Volume
24-06-14 4.88 +5.63% 3,152,000
24-06-13 4.62 -0.65% 2,128,000
24-06-12 4.65 -0.21% 2,836,220
24-06-11 4.66 -2.71% 4,040,000
24-06-07 4.79 -1.84% 1,367,787

Delayed Quote Hong Kong S.E., June 14, 2024 at 04:08 am EDT

More quotes
SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Company’s main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Company’s products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Company’s products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.88 HKD
Average target price
6.227 HKD
Spread / Average Target
+27.60%
Consensus

Annual profits - Rate of surprise